Tag: Ixekizumab

1. Ixekizumab, an IL-17 inhibitor, elicits disease response in patients with non-radiographic active axial spondyloarthritis who have failed treatment with NSAIDs. Evidence Rating Level: 1 (Excellent) Axial spondyloarthritis is a chronic inflammatory disease of the axial skeleton that is typically treated with non-steroidal anti-inflammatory drugs (NSAIDs). Biologic disease-modifying anti-rheumatic drugs (bDMARDs) have...
1. Ixekizumab, an IL-17 inhibitor, elicits disease response in patients with non-radiographic active axial spondyloarthritis who have failed treatment with NSAIDs. Evidence Rating Level: 1 (Excellent) Axial spondyloarthritis is a chronic inflammatory disease of the axial skeleton that is typically treated with non-steroidal anti-inflammatory drugs (NSAIDs). Biologic disease-modifying anti-rheumatic drugs (bDMARDs) have...
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial 1. Obeticholic acid, a farnesoid X receptor agonist, prompts fibrosis improvement in patients with non-alcoholic steatohepatitis (NASH) Evidence Rating Level: 1 (Excellent) Non-alcoholic steatohepatitis (NASH) is an increasingly common cause of chronic liver disease...
1. The use of 120mg ixekizumab in a phase-III, open-label extension (OLE) trial showed improved Psoriasis Area and Severity Index (PASI) outcomes in patients with chronic plaque psoriasis. 2. Ixekizumab was not associated with major cardiac events or deaths in this study. Evidence Rating Level: 2 (Good)            Study Rundown:...